The European Medicines Agency today said it had recommended for EU-wide marketing approval seven new drugs, including two orphans – Roche's Polivy (polatuzumab vedotin), for treating diffuse large B-cell lymphoma (DLBCL), and Novartis's Isturisa (osilodrostat), for the treatment of Cushing’s syndrome.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?